GU Research Network, LLC

Omaha, Nebraska 68130

0 studies enrolling now · 6 studies all time

What they study most

Androgen Resistant Prostatic Cancer, Bone Metastases, Metastatic Castration Resistant Prostate Cancer (mCRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic, Prostate Neoplasms, Various Advanced Cancer

Studies at this site

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent — Stopped early
• A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer — Completed
• Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases — Stopped early
• A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer — Completed